No profile data available.
Genprex, Inc. (GNPX) is a healthcare company in the additional cancer treatment drugs industry, based in Austin, United States, with about 13 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$16.23 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $2.23 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Genprex reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$2.23 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Mustang Bio, Inc. (MBIO), Kairos Pharma, Ltd. (KAPA), BioAtla, Inc. (BCAB), Purple Biotech Ltd (PPBT).